After the successful treatment of inflammatory rheumatic diseases with targeted therapies, the greatest challenge in rheumatic diseases remains the treatment of the most common chronic joint disorder, osteoarthritis (OA). OA is one of the most prevalent chronic diseases worldwide.[@R1] Globally, hip and knee OA is ranked as the 11th highest contributor to global disability (measured by years lived with disability), and as the 38th highest in terms of overall burden (as measured by disability-adjusted life years) in 2010.[@R2] With the aging of the population and rising obesity throughout the world, it is anticipated that the burden of OA will increase and become a major problem for health systems globally.[@R2]

OA commonly affects the knee, with an age-standardised and sex-standardised incidence of 240/100 000 person-years.[@R3] Over the age of 80 years, more than half of women and one-third of men suffer from radiographical OA of the knee.[@R4] The global prevalence of radiographically confirmed knee OA (Kellgren-Lawrence grades 2--4) was very recently estimated to be 3.8% (4.8% in females; 2.8% in males) with a peak at around 50 years of age.[@R2] These data are in agreement with the earlier observation that females are at a higher risk of knee OA than men.[@R5] A recently published cross-sectional analysis found that women also experience greater knee pain than men, regardless of Kellgren-Lawrence grade.[@R6] Pain, inflammatory flares, stiffness and loss of movement and function represent major symptoms of OA including knee OA, resulting in a substantial adverse impact on patients' quality of life and considerable economic burden.[@R3] [@R4] [@R7]

Given this background, proper guidance on the management of OA is needed. This issue has been addressed over recent months in updated guidelines or recommendations from the American Academy of Orthopaedic Surgeons (AAOS), American College of Rheumatology (ACR), European League against Rheumatism (EULAR) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).[@R8] In addition, the OA Research Society International (OARSI) guidelines for the non-surgical management of knee OA were updated and published recently.[@R12] While previous OARSI guidelines addressed the management of hip and knee OA, the updated guidelines focused specifically on the knee, evaluating the safety and efficacy profiles of currently available treatment options.[@R12] Given the relative paucity of novel data, the authors took an innovative approach to enhance the specificity of treatment recommendations: they defined OA clinical subphenotypes (knee-only OA with and without comorbidities; multijoint OA with and without comorbidities).

Commonly, we distinguish three treatment modalities: non-pharmacological, pharmacological and surgical.[@R4] [Figure 1](#RMDOPEN2014000027F1){ref-type="fig"} summarises treatments OARSI recommends are 'Appropriate' in at least one of the four subphenotypes.[@R12] They suggest not using treatments rated 'Inappropriate' (eg, risedronate, electrotherapy), but others are rated 'Uncertain' (eg, acupuncture, chrondroitin, glucosamin or opioids). For the latter, the authors recommend physician--patient interaction to determine whether this treatment may have merit for an individual patient. Referral for consideration of orthopaedic surgical intervention is indicated after more conservative treatment options have been exhausted.[@R12] Although both patients and doctors consider postponing surgery a success, for many patients joint replacement is eventually the final treatment option.[@R13] This implies that, despite the variety of appropriate non-surgical treatment options, there are still considerable limitations in either success rate or tolerability when treating established knee OA.

![Treatments considered 'Appropriate' in at least one of the four subphenotypes of knee osteoarthritis.[@R12] Quality of evidence is indicated by: bold=good; not bold=fair. NSAIDs, non-steroidal anti-inflammatory drug. \* knee braces, knee sleeves, foot orthoses and lateral wedge insoles.](rmdopen2014000027f01){#RMDOPEN2014000027F1}

Excess weight and obesity are well-known risk factors for OA since they increase mechanical stress and induce systemic effects (eg,via adipokines and/or hyperglycaemia) involved in OA pathogenesis.[@R14] It has been recently confirmed that in knee OA, mechanical stress is the most important underlying mechanism; this is in contrast to hand OA, where systemic processes appear to be most important.[@R14] In line with this are results of a meta-analysis published in July 2014 indicating that knee OA risk increases almost exponentially according to the increase in body mass index (BMI).[@R15] Furthermore, analysis of data available through the Osteoarthritis Initiative and the CHECK-cohort confirmed that individuals with higher BMI experience greater pain from knee OA than individuals with lower BMI, even when taking into account OA severity.[@R16] [@R17] Therefore, successful management of knee OA includes reduction of adverse mechanical factors (ie, weight loss in patients who are overweight or obese).[@R11] Exercise is also beneficial, as shown in a recently published randomised controlled trial in women with OA of the knee.[@R18] Progressive resistance exercise reduced pain, improved function, increased strength and showed benefits on some quality of life domains.[@R18] However, apart from these approaches and education about the disease, there is little to offer patients for prevention or early treatment that is directed at the cause of the disease.[@R19]

Why have researchers failed so far to develop effective and safe disease modifying OA drugs (DMOADs) for the millions of patients suffering from this serious and disabling disease? One major reason is that pathogenesis of this disease is not fully understood.[@R13] OA is considered to result from failure of the repair of damaged cartilage.[@R4] However, recent evidence shows an additional and integrated role of bone and synovial tissue, at least in some patients with OA.[@R20] Clearly, OA is not a uniform disease entity. In some patients, progression of the disease seems to be driven by cartilage factors, in others by bone factors or by inflammatory factors.[@R4] [@R21] Ongoing research aims to identify potential biomarkers for cartilage-driven, bone-driven and synovitis-driven forms of OA. In a very recent intriguing study, Beyer *et al*[@R22] identified differentially expressed miRNAs as predictors for severe knee and hip OA. This is an important observation since circulating miRNAs are easily accessible and stable. Only a few biomarkers that reflect bone and cartilage metabolism have shown value in predicting OA,[@R23] and none has so far entered routine clinical practice. Therefore, specific miRNAs, such as let-7e, may prove useful biomarkers for OA.[@R22] Research is also underway into DMOADs that target different aspects of the disease, treatments for OA pain and cell-based therapies; [table 1](#RMDOPEN2014000027TB1){ref-type="table"} lists studies in these areas that we consider promising. Apart from these novel non-surgical approaches, a new surgical method is also in development--intrinsic cartilage repair by joint distraction.[@R21]

###### 

Studies investigating potential new non-surgical treatment options in knee OA (modified and updated from[@R21])

  Treatment option                                      Studies                                                                       Comments
  ----------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------
  DMOADs targeting cartilage                            Intra-articular recombinant human fibroblast growth factor 18 (NCT01919164)   Proanabolic growth factor
  Intra-articular TPX-100 (NCT1925261)                  Chondrogenic peptide                                                          
  DMOADs targeting bone                                 Oral strontium ranelate[@R25]                                                 Remodelling of subchondral bone and articular cartilage
  DMOADs targeting synovitis                            Oral hydroxychloroqine and atorvastatin (NCT01645176)                         A combination of a DMARD with a statin
  Oral methotrexate (NCT01654575)                       A DMARD                                                                       
  Oral SD-6010 (Cindunistat)[@R28]                      Selective inhibitor of inducible nitric oxide synthase                        
  Subcutaneous ABT-981 (NCT01668511)                    Monoclonal antihuman interleukin-1 α/β antibody                               
  Oral PRX167700 (NCT01945346)                          Vascular adhesion protein-1 antagonist                                        
  Treatments targeting pain                             Tanezumab[@R29]                                                               Antinerve growth factor inhibitor
  CG100649 (NCT1765296)                                 Dual inhibitor of carbonic anhydrase and COX-2                                
  AKR 202 (NCT02003118)                                 Small molecule purinergic receptor modulator and enzyme inhibitor             
  Cell-based therapies                                  Allogenic mesenchymal stem cells (NCT01586312, NCT01985633, NCT01459640)      Induction of interactive biological repair mechanisms involving stem cells
  Mesenchymal trophic factor (NCT02003131)                                                                                            
  Autologous adipose derived stem cells (NCT01585857)                                                                                 

The NCT identification number refers to trials registered in ClinicalTrials.gov (<http://clinicaltrials.gov>) where more in detail information can be obtained.

DMOAD, disease-modifying antiosteoarthritic drug; DMARD, disease-modifying antirheumatic drug; OA, osteoarthritis.

Despite these widespread and promising current research activities, many questions about OA and its treatment still require answers ([box 1](#bx1){ref-type="boxed-text"}). The EU has recognised rheumatic and musculoskeletal diseases as 'major diseases', which may trigger research. Priorities in OA research include predictors of progression, understanding mechanisms of pain and tissue communication, developing concepts and interventions for early OA and the need for new treatment strategies.[@R24] This research agenda represents useful guidance for researchers in the field. We believe that putting as much effort into OA research as was seen in recent years in RA research may yield significant progress in improving quality of life for many patients with OA. Real possibilities are visible on the horizon. Box 1Challenges in the treatment of OAWhen does OA start and how can we define this time point?Which programmes are most effective to educate patients about the benefits of current preventive measures (such as weight loss and exercise)?If a novel DMOAD is discovered how can we select patients who will benefit most (different phenotypes, different points of action)?If a novel DMOAD is discovered that needs to be administered before pronounced symptoms develop, will patients adhere to treatment when other preventive measures (such as weight loss and exercise) are currently poorly followed?When should surgery be recommended? At an early time point when quality of life is still good or at a later time because of economic restraints and the limited life span of endoprosthetic material?When will regenerative medicine (including tissue engineering) result in materials to repair damaged joints that provide an alternative to the metal and ceramics currently used?
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